Published in Drug Week, April 23rd, 2004
The designation was granted for the prevention of platinum-induced ototoxicity in pediatric patients.
"FDA orphan drug designation for STS is a major milestone for both children with cancer and for the company," said William P. Peters, CEO and chairman of Adherex. "Hearing loss among children receiving platinum-based chemotherapy is frequent, permanent and severely disabling and affects nearly a third of all children with cancer. Orphan drug designation for STS makes development commercially viable and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.